Yesterday, Aug. 27, 2015, 98 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $287.50 to $3,256,000.00.

Highlighted Stocks Traded by Insiders:

Impax Laboratories (IPXL) - FREE Research Report

Terreri Peter R, who is Director at Impax Laboratories, sold 4,833 shares at $43.93 on Aug. 27, 2015. Following this transaction, the Director owned 39,787 shares meaning that the stake was reduced by 10.83% with the 4,833-share transaction.

Schlossberg Mark A, who is SVP and General Counsel at Impax Laboratories, sold 4,649 shares at $43.41 on Aug. 27, 2015. Following this transaction, the SVP and General Counsel owned 81,045 shares meaning that the stake was reduced by 5.43% with the 4,649-share transaction.

The shares most recently traded at $42.92, down $0.49, or 1.14% since the insider transaction. Historical insider transactions for Impax Laboratories go as follows:

  • 4-Week # shares sold: 100,000
  • 12-Week # shares sold: 100,000
  • 24-Week # shares sold: 100,000

The average volume for Impax Laboratories has been 821,600 shares per day over the past 30 days. Impax Laboratories has a market cap of $3.1 billion and is part of the health care sector and drugs industry. Shares are up 38.79% year-to-date as of the close of trading on Thursday.

Impax Laboratories, Inc., a specialty pharmaceutical company, develops, manufactures, and markets bioequivalent pharmaceutical products. It operates in two segments, Global Pharmaceuticals Division and Impax Pharmaceuticals Division. The company has a P/E ratio of 434.3. Currently, there are 3 analysts who rate Impax Laboratories a buy, 2 analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on IPXL - FREE

TheStreet Quant Ratings

rates Impax Laboratories as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and expanding profit margins. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full

Impax Laboratories Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Servisfirst (SFBS) - FREE Research Report

Rushing Rodney Eldon, who is EVP, Correspondent Banking at Servisfirst, bought 300 shares at $34.79 on Aug. 27, 2015. Following this transaction, the EVP, Correspondent Banking owned 122,300 shares meaning that the stake was boosted by 0.25% with the 300-share transaction.

The shares most recently traded at $36.75, up $1.96, or 5.34% since the insider transaction. Historical insider transactions for Servisfirst go as follows:

  • 4-Week # shares bought: 11,200
  • 4-Week # shares sold: 1,847
  • 12-Week # shares bought: 11,200
  • 12-Week # shares sold: 21,731
  • 24-Week # shares bought: 56,378
  • 24-Week # shares sold: 79,787

The average volume for Servisfirst has been 131,200 shares per day over the past 30 days. Servisfirst has a market cap of $957.9 million and is part of the financial sector and banking industry. Shares are up 12.29% year-to-date as of the close of trading on Thursday.

TheStreet Recommends

ServisFirst Bancshares, Inc. operates as the bank holding company for ServisFirst Bank that provides banking services to individual and corporate customers. The stock currently has a dividend yield of 0.65%. The company has a P/E ratio of 17.1. Currently, there are 3 analysts who rate Servisfirst a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SFBS - FREE

TheStreet Quant Ratings

rates Servisfirst as a

hold

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, compelling growth in net income and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including weak operating cash flow and feeble growth in the company's earnings per share. Get the full

Servisfirst Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Southside (SBSI) - FREE Research Report

Powell Paul, who is Director at Southside, bought 6,839 shares at $25.39 on Aug. 27, 2015. Following this transaction, the Director owned 75,000 shares meaning that the stake was boosted by 10.03% with the 6,839-share transaction.

The shares most recently traded at $25.60, up $0.21, or 0.82% since the insider transaction. Historical insider transactions for Southside go as follows:

  • 4-Week # shares bought: 155
  • 4-Week # shares sold: 1,500
  • 12-Week # shares bought: 155
  • 12-Week # shares sold: 1,500
  • 24-Week # shares bought: 2,206
  • 24-Week # shares sold: 1,500

The average volume for Southside has been 104,300 shares per day over the past 30 days. Southside has a market cap of $635.0 million and is part of the financial sector and banking industry. Shares are down 12.07% year-to-date as of the close of trading on Thursday.

Southside Bancshares, Inc. operates as the holding company for Southside Bank that provides financial products and services to individuals, businesses, municipal entities, and nonprofit organizations. The stock currently has a dividend yield of 3.67%. The company has a P/E ratio of 27.5. Currently, there are no analysts who rate Southside a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SBSI - FREE

TheStreet Quant Ratings

rates Southside as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, expanding profit margins and increase in net income. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full

Southside Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.